Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, L. Green, Monique Topp et al.|Nature Communications|2018Cited by 299
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung Min Lee, Elise C. Kohn, Elizabeth M. Swisher et al.|Journal of Clinical Oncology|2017Cited by 241
Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaKsenija Nesic, Clare L. Scott, Olga Kondrashova et al.|Cancer Research|2021Cited by 91
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerJung Min Lee, Elise C. Kohn, John L. Hays et al.|Oncotarget|2017Cited by 43